{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-056708","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2025-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.590581+00:00","generated_at":"2026-05-24T13:29:18.404528+00:00","sec_items":["2.02","9.01","5.03"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aadi Bioscience relaunches as Whitehawk Therapeutics; reports FY2024 net loss $63.7M, $100M PIPE closed","bullets":["Name changed to Whitehawk Therapeutics; stock begins trading under 'WHWK' on Nasdaq effective March 19, 2025.","Closed $100M PIPE financing; pending divestiture of FYARRO business to Kaken Pharmaceuticals.","Cash position $47.2M at Dec 31, 2024; expected $170-180M after transactions, funding operations into 2028.","FY2024 total revenue $26.0M from FYARRO; net loss $63.7M vs $65.8M in 2023.","ADC portfolio: three assets targeting PTK7, MUC16, SEZ6; goal to bring all to IND within 15 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-056708","json":"https://secwatch.observer/filing/0001193125-25-056708.json","markdown":"https://secwatch.observer/filing/0001193125-25-056708.md","text":"https://secwatch.observer/filing/0001193125-25-056708.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000119312525056708/0001193125-25-056708-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000119312525056708/d839636d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T13:29:18.404528+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a1ec3d3ffca518b10ac72e99423673547e6031c7","claim":"Whitehawk Therapeutics, Inc.: Company amended its certificate of incorporation to change its name from Aadi Bioscience, Inc. to Whitehawk Therapeutics, Inc (effective 2025-03-18).","evidence_excerpt":"The board of directors (the “ Board ”) of the Company approved an amendment to the Company’s amended and restated certificate of incorporation (the “ Charter ”), to change the Company’s name to Whitehawk Therapeutics, Inc. (the “ Name Change ”). On March 18, 2025, the Company filed a certificate of amendment (the “ Name Change Charter Amendment ”) to the Charter with the Secretary of State of the State of Delaware, which effected the Name Change.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312525056708/0001193125-25-056708-index.htm","confidence":0.99,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-03-18"}],"fact_type":"governance_change"},{"claim_id":"c5746f7fa41717529b7d870d299650029e8ca3b7","claim":"Whitehawk Therapeutics, Inc.: Board approved an amendment and restatement of the bylaws solely to reflect the name change to Whitehawk Therapeutics, Inc (effective 2025-03-18).","evidence_excerpt":"Additionally, the Board approved an amendment and restatement of the Company’s bylaws solely to reflect the Name Change (the “ Amended and Restated Bylaws ”). The Amended and Restated Bylaws became effective upon the effectiveness of the Name Change Charter Amendment.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312525056708/0001193125-25-056708-index.htm","confidence":0.99,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2025-03-18"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}